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Background: Amyotrophic lateral sclerosis (ALS) is an incurable fatal motoneuron disease
with a lifetime risk of approximately 1:400. It is characterized by progressive weakness,
muscle wasting, and death ensuing 3–5 years after diagnosis. Granulocyte-colony
stimulating factor (G-CSF) is a drug candidate for ALS, with evidence for efficacy from
animal studies and interesting data from pilot clinical trials. To gain insight into the disease
mechanisms and mode of action of G-CSF, we performed gene expression profiling on
isolated lumbar motoneurons from SOD1G93A mice, the most frequently studied animal
model for ALS, with and without G-CSF treatment.
Results: Motoneurons from SOD1G93A mice present a distinct gene expression profile
in comparison to controls already at an early disease stage (11 weeks of age), when
treatment was initiated. The degree of deregulation increases at a time where motor
symptoms are obvious (15 weeks of age). Upon G-CSF treatment, transcriptomic
deregulations of SOD1G93A motoneurons were notably restored. Discriminant analysis
revealed that SOD1 mice treated with G-CSF has a transcriptom close to presymptomatic
SOD1 mice or wild type mice. Some interesting genes modulated by G-CSF treatment
relate to neuromuscular function such as CCR4-NOT or Prss12.
Conclusions: Our data suggest that G-CSF is able to re-adjust gene expression in
symptomatic SOD1G93A motoneurons. This provides further arguments for G-CSF as a
promising drug candidate for ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegen-
erative disease that results in progressive loss of motoneurons,
motor weakness, and death within 1–5 years after disease onset.
Although more than 130 years have passed since the disease
was first described by Charcot its etiology is still enigmatic, pre-
cluding a truly rational drug development. Motoneurons in the
spinal cord and the motor unit are the common endpoint in all
hypotheses concerning pathophysiology (Gordon, 2013; Turner
et al., 2013). The transgenic SOD-1G93A mice are a model for
ALS and recapitulate most of the ALS pathology, including loss
of motor units. The first evidence of stress on the motor axis
in this model occurs early before appearance of motor deficit
(Frey et al., 2000).
G-CSF was primarily described as a hematopoietic factor able
to stimulate the proliferation and differentiation of myeloid pre-
cursors. It is used for the treatment of chemotherapy-induced
neutropenia and for bone marrow transplants (Kobbe et al., 2009;
Yang et al., 2012). G-CSF has more recently been uncovered as
a neurotrophic factor able to rescue motoneurons from apop-
tosis, protect motor functions and enhance overall survival of
SOD1G93A mice through the preservation of motor units (Pitzer
et al., 2008; Henriques et al., 2010a,b, 2011).
Pilot clinical studies have investigated the potential of G-CSF
as a drug candidate in ALS. Administrations were mainly sub-
cutaneous with limited duration (unique or repeated injection
for up to 5 days) and enrollment ranged from 10 to 39 patients.
Adverse effects were minor and the drug was well tolerated in
all studies. Effects of G-CSF on disease progression are unclear
since all studies suffer from small cohort sizes. One study con-
cluded that G-CSF treatment did not bring benefit for patients
(Nefussy et al., 2010), while others either reported slower dis-
ease progression upon treatment (Martinez et al., 2009; Zhang
et al., 2009), reduced damage of white matter tracts (Duning
et al., 2011) or lower level of pro-inflammatory markers in the
cerebrospinal fluid (Chio et al., 2011).
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Effects of G-CSF treatment in SOD-1G93A mice have been
examined at the clinical, electrophysiological, and histological
level. Here we sought to determine if and what changes on the
gene expression level in alpha motoneurons would be related
to G-CSF treatment. Therefore, our objective was to (1) define
changes on the mRNA level that occur in spinal motoneurons
in an animal model of ALS, the SOD1G93A mice and (2) charac-
terize the effects of G-CSF on detected changes in the transcrip-
tome of those motoneurons. We combined laser microdissection
(LMD), RNA amplification, and gene expression profiling
on DNA arrays to study these cell-type specific expression
changes.
MATERIALS AND METHODS
ALS MODEL
We used mice transgenic for the SOD1G93A mutation (Gurney
et al., 1994) on a C57/bl6 background (B6.Cg-Tg(SOD1-
G93A)1Gur/J strain; Jackson laboratory, Bar Harbor, Maine,
USA), harboring the high copy number of the mutant allele
human SOD1. The hemizygous line was maintained by mat-
ing transgenic males with C57BL/6 wild-type females. Transgenic
littermate females were used in all experiments. They were
either treated with vehicle (250mM sorbitol, 0.004% Tween-
80 and 10mM sodium acetate buffer) or with G-CSF (fil-
grastim dissolved in vehicle, 30µg/kg body weight/day) with
an osmotic, subcutaneously implanted, paravertebrally located
minipump (Alzet Minipump, model 2004; ALZET Osmotic
Pumps, Cupertino, CA, USA) (Pitzer et al., 2008). Wild type
littermates served as control group (group 3). Each mouse was
housed under standard conditions in cages together with 4-6 lit-
termates and fed ad libitum, in a room that also housed male
mice, thus resulting in likely estrous cycle synchronization. All
animal experiments were approved by the Regierungspräsidium
Karlsruhe (Karlsruhe, Germany).
TISSUE ISOLATION
All kinds of surgical instruments (forceps, scissors) were cleaned
with RNase Zap spray or 100 % ethanol before use. Directions
for handling RNA or tissue for RNA isolation (e.g., gloves, etc.)
were followed. For anesthetizing purpose, a mixture of ketamine
(120mg/kg boday mass) and xylasine (Rompun, 16mg/kg body
mass was injected intraperitoneally. After complete absence of
peripheral nociceptive reflexes the animals were perfused tran-
scardially via the left ventricle with ice-cold HBSS. The pump
was run at 10ml/min for 3min. Care was taken not to injure
any blood vessel during the preparation. The perfused mouse was
fixed onto ametal platform cooled by wet ice to avoid RNA degra-
dation. After removal of the skin, cranial bones and vertebrae
were carefully removed dorsally and spinal cords were dissected
from the remaining opened cranium and vertebral canal. The tho-
racic position T9 was marked with a blue dye spot. Tissue was
frozen on dry ice for about 5–10min and stored at −80◦C.
LASER MICRODISSECTION
Spinal cords were cryosectioned into 8µm coronal sections, start-
ing at the lumbar position L2. Thirty sections per mice were
collected. Sections taken for microdissection were 100µm apart.
The tissue on the POL-membrane of a frame slide was overlaid
with thionin staining solution so that the whole sample was com-
pletely covered. After 20 s ultraPURE™ water was poured onto
the sample to wash away excess thionin. The frame slide with
the tissue sample on the POL-membrane was mounted onto the
microscope. Samples were collected into the cap of a 0.65ml
LMD tube filled with 35µl of buffer RLT (Qiagen RNeasy®Micro
Kit). Using the program “Leica Laser Microdissection V 5.0,” cells
were marked and then automatically cut by a moving laser beam
(power 40–50, speed 4, specimen/balance 11, offset 45). A total of
300 motoneurons per mouse spinal cord have been sampled by
laser microdissection (Supplementary Figure 1), from a total of
35mice (week 11 wt: n = 6; SOD n = 8); week 15 [wt n = 7; SOD
(vehicle): n = 7; SOD (G-CSF treated): n = 7)], and subjected
amplified RNA to array hybridization. Cutting was done at 40x
magnification. Experimenters involved in laser microdissection
were blind to the identity of the animal.
RNA AMPLIFICATION
Each RNA sample was linearly amplified by two consecutive
rounds of T7 polymerase-driven amplification. The precipi-
tated total RNA of each LMD sample was reverse transcribed
with a first-strand synthesis mix comprising 10 U Superscript
III (Invitrogen, Karlsruhe, Germany), 1 U Superasin (Ambion,
Huntingdon, UK) and 0.5 pmol of T7-T18V primer by incu-
bating for 2 h at 50◦C after second-strand synthesis with 6 U
DNA polymerase I, 2 h at 22◦C with 0.2 U RNaseH, and 15min
at 16◦C with 4 U T4 DNA polymerase I (Invitrogen). The T7
promoter tagged cDNA template was purified by standard phe-
nol extraction and ethanol precipitation. This cDNA was used
for first round amplified antisense RNA production applying a
MegaScript kit (Ambion) and purified with an RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. Second
round amplification was performed accordingly but using T7-
tagged random primer for first strand cDNA synthesis and T18V
primer for second-strand synthesis, yielding amplified sense
RNA. UVmeasurements at 280 and 260 nm and 2100 Bioanalyzer
runs using the RNA-6000 Nano-LabChip (Agilent, Böblingen,
Germany) were used to ensure the quality and quantity of the
sense RNA produced. Only samples showing RNA integrity num-
bers (RIN) above 8 were used. The yield varied from 40 to
80µg.
ARRAY ANALYSES
The arrays were performed with the GeneChip® mouse genome
430 2.0 array from Affymetrix (Affymetrix, Santa Clara, CA,
USA). Expression console software (Affymetrix, Santa Clara, CA,
USA) was used to normalize arrays with the gcrma algorithm
(Harr and Schlotterer, 2006) and to perform quality control. The
database was filtered with intensity and standard deviation. We
removed genes when one of the following conditions was not met:
less than 4 arrays had intensity higher than the centile 20% of all
genes or the standard deviation was lower than centile 30% of all
genes.
Discriminant analysis has been performed with JMP 11.0.0
(SAS Institute, Cary, North Carolina) with genes presenting a
minimum standard deviation greater than 1.2 in all individuals.
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Class prediction has been computed using a non-parametric
k-Nearest Neighbors algorithm.
Differential gene expression among experimental groups has
been assessed by ANOVA followed by a post-hoc Tukey’s Honest,
with genes presenting a minimum fold-change of 1.5-fold. We
considered a p-value lower than 0.05 with a FDR lower than 10%
as significant difference. Analyses were performed using BRB-
ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools
Development Team (http://linus.nci.nih.gov).
WEB-based Gene SeT AnaLysis Toolkit was used to detect
enrichment of biological functions (WebGestalt, http://bioinfo.
vanderbilt.edu/webgestalt/) (Zhang et al., 2005; Wang et al.,
2013).
REAL-TIME QUANTITATIVE PCR
One µg total RNA used for the microarray was used to synthe-
size cDNA using superscript II reverse transcriptase (Invitrogen)
and oligo-dT primers, accordingly to manufacturer’s recom-
mendation. Quantitative reverse transcription-polymerase chain
reaction was performed using the Lightcycler system with SYBR-
Green reagent (Roche). Cycling conditions were as follows:
10min at 95◦C; 5 s at 95◦C, 10 s at the annealing temperature of
64◦C, 30 s at 72◦C for 50 cycles and 10min at 95◦C. Relative quan-
tification were calculated after normalization to the reference gene
cyclophilin B.
RESULTS
DESIGN OF THE EXPERIMENT
A first group of SOD1G93A and WT mice was included in the
study at week 11 of age when SOD1G93A mice present no signs
of motor dysfunction but subtle signs of denervation detectable
by electromyography (Pitzer et al., 2008). The second cohort of
mice was treated with G-CSF or vehicle from week 11 to week 15.
At the time of study completion, SOD1G93A mice presented clear
motor impairment andmotoneuron degeneration is documented
(Pitzer et al., 2008; Henriques et al., 2011).
During laser microdissection, there is a risk of collecting cells
surrounding motoneurons and therefore analyzing non-neuronal
transcripts (Supplementary Figure 1A, Perrin et al., 2005;
Bandyopadhyay et al., 2013). To assess the proportion of con-
taminating RNA, we have studied the expression values of highly
specific markers for astrocytes, oligodendrocytes, microglia,
endothelial cells, and neurons (Cahoy et al., 2008). All exper-
imental groups show high expression of the specific neuronal
markers, while markers for glial and endothelial cells are present
at very low levels or not detected (Supplementary Figure 1B).
These data suggest that contamination with RNA from other cells
than motoneurons is minimal and irrelevant for the following
analyses.
The design of the present study should be informative on genes
altered in motoneurons of SOD1G93A mice from the clinically
non-symptomatic to an early symptomatic stage, and give insight
into genes influenced by G-CSF treatment (Figure 1A). Results
were analyzed by unsupervised and supervised approaches
(Figure 1B), and biological functions for relevant genes analyzed
based on gene ontology.
FIGURE 1 | Study design. (A) Time course of the study. Given is the
disease course in SOD1G93A mice, time of treatment and time of sacrifice
for all experimental groups. (B) Flow chart for analytical steps for analysis.
GENE REGULATION IN SOD1G93A MOTONEURONS
At 11 weeks of age, when SOD1G93A mice do not show motor
symptoms despite early electromyographic changes we detected
985 transcripts with a significantly altered expression, of which
725 genes were upregulated and 260 dowregulated (Table 1).
At 15 weeks of age, when motor symptoms are obvious and
muscular denervation signs are prominent by electromyogra-
phy, the number of significantly deregulated transcripts was two
times higher, with 790 genes upregulated and 1245 dowregulated
(Table 2). Functional annotation using gene ontology revealed
that metabolic process, reponse to stimulus/stress and nucleic
acid binding were the main biological and molecular functions
altered in SOD-1 motoneurons (Supplementary Figure 2).
At the presymptomatic disease stage (week 11), genes which
were most downregulated were the collectin sub-family member
11 (colec11) and vacuolar protein sorting 4b (vpsb4) (Table 1).
Expression of colec11 has been reported in neurons and is
involved in innate immunity (Motomura et al., 2008; Ohtani
et al., 2012). vpsb4 is known to interact with the pro-apoptotic
pathway (Cui et al., 2014) and the autophagosome in neurode-
generative conditions (Han et al., 2012). Themost strongly upreg-
ulated genes were related to response to stress and injury, such
as activating transcription factor 3 (atf3) and small proline-rich
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Table 1 | List of the main transcripts whose expression are altered in SOD1G93A mice at 11 week of age.
Probe set ID Symbol Name FC p-value
1458345_s_at Colec11 Collectin sub-family member 11 0.28 0.005
1457067_at Vps4b Vacuolar protein sorting 4b (yeast) 0.32 0.016
1444869_at – – 0.34 0.001
1427351_s_at Ighm Immunoglobulin heavy constant mu 0.34 0.000
1419332_at Egfl6 EGF-like-domain, multiple 6 0.38 0.000
1423608_at Itm2a Integral membrane protein 2A 0.38 0.000
1438763_at Dnahc2 Dynein, axonemal, heavy chain 2 0.39 0.000
1435815_at Ldoc1 Leucine zipper, down-regulated in cancer 1 0.40 0.000
1423390_at Siah1a Seven in absentia 1A 0.41 0.000
1418916_a_at Spp2 Secreted phosphoprotein 2 0.43 0.000
1441114_at 9330156P08Rik RIKEN cDNA 9330156P08 gene 0.44 0.004
1420386_at Seh1l SEH1-like 0.45 0.005
1419435_at Aox1 Aldehyde oxidase 1 0.46 0.001
1445767_at Ptprd Protein tyrosine phosphatase, receptor type, D 0.46 0.001
1452276_at Smarcad1 SWI/SNF-related, matrix-associated actin-dependent regulator of
chromatin, subfamy a, containing DEAD/H box1
0.46 0.013
1437796_at – – 0.46 0.000
1427196_at Wnk4 WNK lysine deficient protein kinase 4 0.46 0.016
1451440_at Chodl Chondrolectin 0.46 0.000
1439011_at Gm20245 Predicted gene, 20245 0.46 0.044
1438143_s_at Atxn2 Ataxin 2 0.47 0.000
1449662_at Reep1 Receptor accessory protein 1 4.0 0.0000
1434442_at Stbd1 Starch binding domain 1 4.0 0.0001
1426851_a_at Nov Nephroblastoma overexpressed gene 4.1 0.0003
1426808_at Lgals3 Lectin, galactose binding, soluble 3 4.2 0.0000
1440142_s_at Gfap Glial fibrillary acidic protein 4.4 0.0000
1419665_a_at Nupr1 Nuclear protein 1 4.5 0.0000
1423427_at Adcyap1 Adenylate cyclase activating polypeptide 1 4.9 0.0002
1449519_at Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 5.1 0.0000
1417022_at Slc7a3 Solute carrier family 7, member3 5.1 0.0000
1451285_at Fus Fusion, derived from t(12;16) malignant liposarcoma (human) 5.6 0.0060
1417868_a_at Ctsz cathepsin Z 5.7 0.0000
1422916_at Fgf21 Fibroblast growth factor 21 6.1 0.0000
1437621_x_at Phgdh 3-phosphoglycerate dehydrogenase 8.3 0.0000
1437232_at Bpifc BPI fold containing family C 8.4 0.0000
1454714_x_at Phgdh 3-phosphoglycerate dehydrogenase 8.7 0.0000
1434129_s_at Lhfpl2 Lipoma HMGIC fusion partner-like 2 10.6 0.0000
1449153_at Mmp12 Matrix metallopeptidase 12 12.3 0.0002
1449133_at Sprr1a small proline-rich protein 1A 13.7 0.0000
1449363_at Atf3 activating transcription factor 3 14.4 0.0000
repeat protein 1A (sprr1A). Upregulation of atf3 has already been
noted in motoneurons after axotomy (Tsujino et al., 2000) and
in response to deficiency in neurotrophic factors (Hyatt Sachs
et al., 2007). Sprr1A was the second most stimulated gene and,
similar to atf3, its expression is enhanced in motoneurons upon
axotomy in order to promote axonal growth (Bonilla et al., 2002;
Li and Strittmatter, 2003; Starkey et al., 2009). Interestingly,
the fus (fused in sarcoma) gene was strongly upregulated in
the presymtomatic disease stage. Fus protein is a RNA-binding
protein and has important functions in RNA metabolism (e.g.
splicing, formation of stress granule, transport and local trans-
lation). Mutations in fus are found in familial forms of ALS, and
inclusions of the protein are present in patients with frontotem-
poral dementia, a syndrome that is connected to ALS (Ling et al.,
2013).
At the symptomatic disease stage, the most overexpressed
genes were mainly associated with motoneuron stress response
and support of axonal regeneration, similar to the presymp-
tomatic disease stage (Table 2). Beside sprr1A and atf3, the
growth associated protein 43 (gap43) shows increased expres-
sion (9-fold) which is involved in axonal regeneration after
motoneuron injury (Chen et al., 2010; Grasselli et al., 2011).
Interestingly, the transcription factor responsible for sprr1A
expression in motoneurons, sox11, is strongly upregulated at
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Table 2 | List of the main transcripts whose expression are altered in SOD1G93A mice at 15 week of age.
Probe set ID Symbol Name FC p-value
1457587_at Kcnq5 Potassium voltage-gated channel, subfamily Q, member5 0.08 0
1423608_at Itm2a Integral membrane protein 2A 0.1 0
1427329_a_at Ighm Immunoglobulin heavy constant mu 0.12 0
1427351_s_at Ighm Immunoglobulin heavy constant mu 0.13 0
1451440_at Chodl Chondrolectin 0.13 0
1451047_at Itm2a Integral membrane protein 2A 0.14 0
1429759_at Rps6ka6 Ribosomal protein S6 kinase polypeptide 6 0.15 0
1445268_at – – 0.15 0
1455291_s_at Znrf2 Zinc and ring finger 2 0.17 0.001
1455238_at Mum1l1 Melanoma associated antigen (mutated) 1-like 1 0.17 0
1449155_at Polr3g Polymerase (RNA) III (DNA directed) polypeptide G 0.17 0
1433898_at – – 0.17 0
1441801_at Kctd4 Potassium channel tetramerisation domain containing 4 0.18 0
1452366_at Csgalnact1 Chondroitin sulfate n-acetylgalactosaminyltransferase 1 0.18 0
1418469_at Nrip1 Nuclear receptor interacting protein 1 0.18 0.005
1434102_at Nfib Nuclear factor i/b 0.18 0
1433827_at Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 0.19 0
1438214_at Trps1 Trichorhinophalangeal syndrome I (human) 0.19 0.003
1422880_at Sypl Synaptophysin-like protein 0.19 0
1460227_at Timp1 Tissue inhibitor of metalloproteinase 1 4.8 0.0001
1434376_at Cd44 CD44 antigen 5.2 0.0013
1434129_s_at Lhfpl2 Lipoma HMGIC fusion partner-like 2 5.6 0
1423427_at Adcyap1 Adenylate cyclase activating polypeptide 1 5.6 0.0002
1426852_x_at Nov Nephroblastoma overexpressed gene 5.9 0
1448471_a_at Ctla2a Cytotoxic T lymphocyte-associated protein 2 alpha 5.9 0.0065
1429051_s_at Sox11 SRY-box containing gene 11 6 0.0003
1454714_x_at Phgdh 3-phosphoglycerate dehydrogenase 6.4 0
1437726_x_at C1qb Complement component 1, q subcomponent, beta polypeptide 6.6 0
1436996_x_at Lyz1 Lysozyme 1 6.7 0.0054
1450792_at Tyrobp TYRO protein tyrosine kinase binding protein 7.1 0.0002
1437621_x_at Phgdh 3-phosphoglycerate dehydrogenase 7.8 0
1423760_at Cd44 CD44 antigen 7.9 0.0003
1434046_at AA467197 Expressed sequence AA467197 8.3 0.0001
1426808_at Lgals3 Lectin, galactose binding, soluble 3 8.9 0
1423537_at Gap43 Growth associated protein 43 8.9 0
1449363_at Atf3 Activating transcription factor 3 10 0
1440142_s_at Gfap Glial fibrillary acidic protein 13 0
1449133_at Sprr1a Small proline-rich protein 1A 20.6 0
this disease stage. Potassium voltage-gated channel, subfam-
ily Q, member 5 (kcnq5) was the most downregulated gene
(downregulated 14-fold) at the symptomatic disease stage. Its
function in motoneurons is not described, but should be
related to the control of resting and release properties of
synapses (Huang and Trussell, 2011). The expression of chon-
drolectin (chodl) was also strongly repressed in motoneurons
of SOD1G93A mice. Interestingly, this protein promotes motor
axon growth and growth cone interactions, and its downregu-
lation is associated with motoneuron degeneration in an ani-
mal model of spinal muscular atrophy (Zhong et al., 2012;
Sleigh et al., 2014). As shown in Supplementary Table 1, 83
transcripts were commonly deregulated at both asymptomatic
and symptomatic disease stages. We noted deregulation at the
two disease stages for several growth factors (FGF21, VGF,
TGFa), and genes related to DNA/RNAmetabolism (wars, eef1a1,
eif4e).
G-CSF PARTIALLY RESTORES THE MOTONEURON TRANSCRIPTIONAL
SIGNATURE IN SOD1G93A MICE
In order to better understand the effects of G-CSF in the
SOD1G93A mice, we have monitored transcriptional changes in
motoneurons at a symptomatic disease stage upon a 4 weeks treat-
ment (from week 11 to week 15). We performed a discriminant
analysis with transcripts showing a standard deviation greater
than 1.2 across all samples (734 transcripts).
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As shown in a canonical plot, control groups are close to
each other and SOD1G93A mice are distant from non-transgenic
animals (Figure 2A). The SOD1 mice treated with G-CSF (green
dots in Figure 2) tended to have a transcriptomic signature dif-
ferent from the sympatomatic SOD1 mice (red dots in Figure 2),
that was closer to non-symptomatic mice. This observation was
further confirmed by class prediction using a non-parametric
k-Nearest Neighbors algorithm, used to predict the class of
unknown samples. The algorithm was built with the signatures of
all samples with the exclusion of mice treated with G-CSF. There
were 4 defined classes: wild type 11 weeks, SOD-1G93A 11 weeks
(presymptomatic), wild type 15 weeks and SOD-1G93A mice 15
weeks (symptomatic). SOD-1G93A mice treated with G-CSF were
considered as unknown and the algorithm sorted them into the
defined classes based on their transcriptome signature. The mean
percent of correct classification reached 96% of efficacy for the
defined classes, with a sensitivity above 0.875 and a specificity of
0.955.
The group treated with G-CSF was composed by seven SOD-
1G93A mice. Three out of seven were sorted as symptomatic
SOD-1G93A, one as asymptomatic SOD-1G93A 11 weeks, and three
as wild type 15 weeks (Figure 2B). These data suggest that G-CSF
can modulate the gene expression in motoneurons of 15 weeks
old SOD-1G93A mice and can prevent disease-related changes
to approach the transcriptomic signature of healthy mice or
asymptomatic SOD1G93A animals.
GENES REGULATED BY G-CSF IN MOTONEURONS OF SOD1G93A MICE
Next, we focused on the identity of differentially expressed
genes in motoneurons after G-CSF treatment. G-CSF had an
effect on the regulation of 463 transcripts in total, and was
able to adjust the expression of 187 transcripts that were either
FIGURE 2 | Canonical plot shows dispersion of treated animals off the
non-treated groups. Multivariate analyses have been conducted with
genes having a standard deviation greater than 1.2 (734 transcripts). (A)
Canonical plot shows that symptomatic SOD-1 mice (red dots) are distant
from other groups, including asymptomatic SOD1 mice (blue dots) and
when considered as unknown, SOD-1 mice treated with G-CSF (green
dots) show a strong dispersion and tend to be close to wild types at 11
weeks (gray dots) or 15 weeks of age (black dots). (B) After G-CSF
treatment, discriminant analysis classified only three samples of SOD1
motorneurons as symptomatic motor neurons. One sample was
considered has presymptomatic and three as wild type motor neurons.
up- or downregulated in SOD1G93A mice compared to controls
(Tables 3, 4, Figure 3).
Two of the most downregulated transcripts in SOD1G93A mice,
kcnq5 and larp4, had their expression enhanced by a factor 3
upon G-CSF treatment as compared to placebo group. Larp4
has no known specific functions in neurons but is known to
regulates mRNA stability (Yang et al., 2011). G-CSF prevented
the upregulation of NPY, a well-known neuropeptide involved
in energetic metabolism and food intake but also expressed by
neurons in response to stress such as spinal cord inflammation
(Taylor et al., 2014). Upregulation of cklf, a cytokine with lym-
phocyte chemoattractive properties, was also inhibited by treat-
ment (Han et al., 2001). Interestingly, Cpt1a and elovl4, two
transcripts directly associated with lipid metabolism, were down-
regulated in SOD1G93A motoneurons, and upregulated by G-CSF.
Cpt1a controls the entrance of fatty acids into mitochondria and
is therefore the rate limiting enzyme for fatty acid oxidation, and
Elovl4 elongates long fatty acids without distinction on their satu-
ration levels, suggesting that G-CSF could enhance the processing
of fatty acids in spinal cord. Additionally, G-CSF modulated the
expression of 251 previously unaltered transcripts. The effect
of G-CSF was prominent on gene ontology biological functions
deregulated in SOD1G93A mice, including metabolic process, and
response to stimulus (Supplementary Figure 2).
In order to assess the reliability of the analysis, we selected sev-
eral genes for validation by quantitative real time PCR (qPCR).
Those genes were selected because of their altered expression in
SOD1G93A mice at 15 weeks of age and by a significant effect
of G-CSF on their regulation. An additional criterion was their
potential role in the neurodegenerative process of ALS based
on the literature. We chose to study the regulation of CNOT10,
CTSB, Prss12 and BMPR1a. CNOT10 is a member of the CCR4-
NOT complex that acts as a chaperon platform (Collart and
Panasenko, 2012). The CCR4-NOT complex controls and pro-
motes neuromuscular junction formation in drosophila (Pradhan
et al., 2012). Prss12, also known as motopsin, is a protease specific
to neurons and its expression is downregulated upon stress, such
as axotomy, in motoneurons (Numajiri et al., 2009). Its regula-
tion is therefore seen as a marker of denervation. We chose ctsb,
as meta-analysis of transcriptomic studies in ALS have shown
its expression systematically altered, both in human patients and
SOD1G93A mice (Saris et al., 2013). Ctsb codes for cathepsin B, a
protein associated with neuroinflammation, motoneuron degen-
eration, and tissue destruction (Kikuchi et al., 2003). BMPR1a
is a receptor serine/threonine kinase and regulates apoptosis
and cell differentiation (Mishina et al., 2004). In the central
nervous system, BMP signaling is required during formation
of large-transmitting synapses (Xiao et al., 2013), build-up of
neuromuscular junctions (Higashi-Kovtun et al., 2010) and is
stimulated upon spinal cord and sciatic nerve injury (Tsujii et al.,
2009; Sahni et al., 2010).
Relative expressions for these transcripts were highly simi-
lar to the relative abundance derived from microarray analyses
(Figure 4). In particular, upregulation of CNOT10 present in
SOD1G93A mice is completely reversed upon G-CSF treatment.
The regulation of bmpr1a showed a trend to the wild type value
but this was not significant in the qPCR analysis.
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Table 3 | List of the main transcripts whose expression is downregulated by G-CSF treatment in SOD1G93A mice at 15 week of age.
Probe set ID Gene symbol p-value WT SOD1 SOD1 G-CSF FC WTvsSOD1 FC WT vs. SOD1-GCSF
1421979_at Phex 0.000 1.994 4.091 1.983 4.279 0.992
1421316_at Lce1g 0.001 2.505 4.563 2.415 4.167 0.940
1419127_at Npy 0.000 4.025 6.074 4.075 4.138 1.035
1456084_x_at Fmod 0.000 2.536 4.400 2.752 3.640 1.161
1437720_at Eif2d 0.000 4.914 6.458 5.661 2.916 1.679
1438856_x_at Serpinb5 0.018 2.880 4.356 2.842 2.781 0.974
1441836_x_at Gtsf1 0.003 2.524 3.958 2.718 2.703 1.144
1444780_at Nav2 0.001 3.251 4.684 3.440 2.700 1.140
1418778_at Ccdc109b 0.001 3.279 4.642 3.071 2.571 0.865
1437775_at Dlst 0.003 4.229 5.570 4.142 2.532 0.941
1448048_at Nmrk1 0.006 2.889 4.219 2.927 2.515 1.027
1458056_at Srek1 0.003 2.954 4.280 3.260 2.507 1.236
1454557_at 6720454L07Rik 0.000 3.338 4.651 3.503 2.485 1.122
1417491_at Ctsb 0.000 6.668 7.909 7.128 2.364 1.376
1436242_a_at Cklf 0.019 6.877 8.107 6.819 2.346 0.961
1458335_x_at Urm1 0.000 6.757 7.911 7.240 2.225 1.398
1428514_at Cpne3 0.000 2.936 4.085 3.124 2.218 1.139
1456816_at Zmiz1 0.001 3.413 4.530 3.732 2.170 1.248
1433733_a_at Cry1 0.001 2.270 3.378 2.549 2.155 1.213
1418467_at Smarcd3 0.000 4.533 5.617 5.038 2.121 1.419
1429688_at Arntl2 0.014 2.893 3.971 2.846 2.111 0.968
1460578_at Fgd5 0.000 3.593 4.669 3.192 2.108 0.757
1457147_at Etl4 0.001 3.500 4.570 3.118 2.099 0.767
1437822_at Yme1l1 0.004 3.426 4.485 3.395 2.084 0.979
1458669_at Agpat5 0.003 3.253 4.304 3.132 2.073 0.919
1443883_at Sys1 0.000 4.305 5.316 4.112 2.015 0.875
1433882_at Cnot10 0.000 5.577 6.566 5.363 1.985 0.862
1437718_x_at Fmod 0.000 2.890 3.862 2.837 1.961 0.964
1440398_at 0.001 2.641 3.608 2.866 1.954 1.169
1445861_at Usp25 0.014 3.428 4.393 3.399 1.952 0.980
1443242_at D5Ertd121e 0.005 2.186 3.150 2.205 1.950 1.013
Taken together, these data demonstrate that G-CSF pro-
motes transcriptional changes in motoneurons in symptomatic
SOD1G93A mice and can correct the alterations of many disease
related gene expression changes.
DISCUSSION
ALS is a fatal condition characterized by the constant death of
motoneurons. Although the triggering factors for ALS remain
unknown, the step that induces symptoms is the disruption of the
motor units, with the dismantlement of neuromuscular junctions
and motoneuron stress and death. The study of global changes in
the transcriptome of specific cells in the motor axis is a promis-
ing approach to address the complexity of ALS (Henriques and
Gonzalez De Aguilar, 2011).
TRANSCRIPTOMIC CHANGES OF MOTONEURONS FROM SOD1G93A
MICE
Here, we studied the transcriptome of motoneurons of SOD1G93A
mice, at two disease stages and after a pharmacological treatment
with G-CSF, a trophic factor with neuroprotective properties
(Pitzer et al., 2008; Henriques et al., 2010a,b, 2011). Our aim was
to characterize the transcriptomic reponse of motor neurons to a
neuroprotective treatment based on G-CSF.
In 2005, a first study was published describing the tran-
scriptome of laser microdissected motoneurons of SOD1G93A
mice at three different disease stages (Perrin et al., 2005). The
conclusion of the authors was that few changes occurred at
presymptomatic (28 deregulated transcripts) and early symp-
tomatic (148 deregulated transcripts) stages, and that symp-
tomatic stages were characterized by few expression changes in
cell-death-associated genes. They found deregulation of related
to energetic metabolism, cell growth and/or maintenance (Perrin
et al., 2005). Many of these genes also showed an altered expres-
sion in our study. In 2007, another group published data on
the transcriptome of dissected motoneurons from SOD1G93A
mice, and reported dysregulations on genes related to transcrip-
tion and nuclear proteins, protein synthesis, metabolism and
cell cycle/growth (Ferraiuolo et al., 2007). Both studies identi-
fied lower deregulation events than our study. This difference can
most likely be explained by higher statistical power in our study
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Table 4 | List of the main transcripts whose expression is upregulated by G-CSF treatment in SOD1G93A mice at 15 week of age.
Probe set ID Gene symbol p-value WT SOD1 SOD1 G-CSF FC WTvsSOD1 FC WT vs. SOD1-GCSF
1457587_at Kcnq5 0.000 7.713 4.026 5.814 0.078 0.268
1455102_at Larp4 0.000 6.999 4.642 6.371 0.195 0.647
1455381_at Marf1 0.002 7.906 5.585 7.319 0.200 0.666
1449861_at Nek4 0.001 5.754 3.478 5.055 0.207 0.616
1460440_at Lphn3 0.000 6.848 4.670 6.104 0.221 0.597
1419555_at Elf5 0.000 5.646 3.526 5.185 0.230 0.727
1455960_at Megf9 0.000 6.959 4.882 6.446 0.237 0.701
1429475_at Ubash3b 0.001 6.351 4.279 5.680 0.238 0.628
1420388_at Prss12 0.000 7.504 5.467 6.385 0.244 0.461
1449348_at Mpp6 0.000 8.104 6.114 7.248 0.252 0.552
1438435_at Acer3 0.001 4.492 2.529 4.626 0.257 1.098
1429107_at Ubr3 0.001 6.415 4.532 5.996 0.271 0.748
1451217_a_at Immp1l 0.000 6.378 4.530 6.677 0.278 1.230
1419357_at Isy1 0.000 5.599 3.778 5.114 0.283 0.715
1423597_at Atp8a1 0.000 8.998 7.187 8.151 0.285 0.556
1418973_at Blzf1 0.000 6.188 4.426 5.637 0.295 0.683
1454937_at B630005N14Rik 0.000 6.420 4.661 5.956 0.295 0.725
1435224_at Crebbp 0.015 7.833 6.076 7.621 0.296 0.863
1455728_at Pten 0.001 5.930 4.204 5.737 0.302 0.875
1416468_at Aldh1a1 0.000 8.034 6.314 7.206 0.304 0.563
1425493_at Bmpr1a 0.000 4.559 2.907 4.253 0.318 0.809
1417564_at Med7 0.000 7.151 5.551 6.891 0.330 0.835
1423298_at Add3 0.000 7.243 5.681 6.749 0.339 0.710
1421904_at Tgs1 0.001 8.757 7.283 8.236 0.360 0.697
1416655_at C1galt1c1 0.001 9.662 8.190 9.617 0.360 0.969
1460409_at Cpt1a 0.000 8.140 6.686 7.440 0.365 0.616
1451308_at Elovl4 0.000 6.986 5.539 6.436 0.367 0.683
1423490_at Fbxo3 0.000 8.932 7.495 8.538 0.369 0.761
1455807_at Tspyl5 0.001 7.369 5.965 6.909 0.378 0.727
as both studies used fewer animals (n = 3/group) than our study
(at least n = 6 per group). Higher degree of contaminating RNA
from motoneuron-surrounding cells could also account for the
differences between studies.
Based on our results, the transcriptome of isolated motoneu-
rons of SOD1G93A mice is characterized by the deregulation
of genes, starting at presymptomatic disease stages, related to
response to stress, to regulation of transcription and to metabolic
processes.
Response to stress is stimulated early on, at presymptomatic
disease stage. Trophic signaling seems also to be stimulated,
with the upregulation of the trophic factors such as fgf21 and
vgf at presymptomatic and symptomatic disease stages. FGF21
belongs to the fibroblast growth factor family, known to counter-
act motoneuron death after axotomy-induced apoptosis (Cuevas
et al., 1995), but also shown to regulate activation of astrocytes
in animal models of ALS (Cassina et al., 2005). Additionally,
motoneurons of SOD1G93A show an upregulation of transcrip-
tion factors related to stress response, that are also closely
connected to trophic factors, such as ATF3 (Averill et al., 2004).
During laser-microdissection of motoneurons, small amount
of astrocyte RNA may have been captured. Although this
contamination is minimal in our study, genes that are expressed
at low abundance in motoneurons but at high levels in glial
cells could be detected as differentially regulated, provided that
the difference between two groups is very strong. An indi-
cation for that could be the detection of GFAP among the
deregulatated transcripts in our study (upregulated in SOD1
mice). Presence of transcripts of glial origin in studies work-
ing on laser-captured motoneurons has been described previ-
ously (Perrin et al., 2005; Ferraiuolo et al., 2007). Therefore,
it is possible that the alterations in the transcriptome linked
to energetic/lipid metabolism arise from astrocytes surrounding
motoneurons. G-CSF was indeed interestingly able to stimulate
the expression of cpt1a in SOD1G93A mice, which is surprising
since fatty acids are not the main energetic source for neu-
rons. It is therefore possible that upregulation of cpt1a takes
place in astrocytes and not in motoneurons, presumably to
sustain higher energetic needs for neurons. Indeed, during ener-
getic stress, astrocytes are able to convert lipid to ketone bod-
ies that will be used as energetic fuel by surrounding neurons
(Guzman and Blazquez, 2004). Interestingly, recent studies have
shown increased ketone bodies in the cerebrospinal fluid of
patients and fatty acid and ketone body supplementations have
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FIGURE 3 | G-CSF treatment modulates transgene-related gene
expression changes. (A) Chart showing the number of differentially
regulated genes after G-CSF treatment in the motoneurons of SOD1 mice.
(B–C) Given is the relative expression of the 30 most significantly modified
transcripts re-adjusted by G-CSF treatment and previously found
downregulated (B) or upregulated (C) in symptomatic SOD1 mice.
neuroprotective effects on motoneurons in animal models of ALS
(Blasco et al., 2010; Schmitt et al., 2014). Energetic metabolism
represents one promising field of research in ALS. Patients present
with hypermetabolism, higher energetic needs and a higher level
of circulating lipids is associated with better survival (Schmitt
et al., 2014). Two recent clinical reports strongly suggest benefit
after high lipid/caloric diets in ALS patients with a strong effect
on survival (Dorst et al., 2013; Wills et al., 2014).
We found deregulation of several genes associated to RNA
metabolism, such as Wars, Eef1a1 and Eif4e. Growing evidence
suggests a role for defect RNA processing in motoneuron death.
ALS patients present pathological inclusion of TDP-43 and FUS,
two proteins that closely interact with RNA metabolism (Ling
et al., 2013). Mutations in TARDBP (coding for TDP-43) and
FUS are described in ALS patients with a family history but also
in patients with fronto-temporal dementia (FTD) with a high
risk (around 30%) to develop ALS. Expanded repeats in the gene
C9orf72 are largely present in sporadic and familial ALS and
FTD cases. Interestingly, whose expanded repeats are believed to
induce RNA toxicity through a novel negative gain-of-function.
Our results therefore provide interesting new clues when related
to most recent pathophysiological hypotheses in ALS research.
FIGURE 4 | Validation of the expression of selected transcripts by
qPCR. (A–D) Expression levels from microarray analyses of Bmpr1a (A),
CNOT10 (B), CTSB (C) and PRSS12 (D) at the symptomatic disease stage.
(E–H) Expression levels derived from quantitative PCR of Bmpr1a (E),
CNOT10 (F), CTSB (G) and PRSS12 (H) at the symptomatic disease stage.
Data are presented as mean ± standard variation of the mean. ∗p < 0.05
(ANOVA, followed by multicomparison t-test).
G-CSF ACTION ON MOTONEURONS
Our transcriptomic study describes for the first time the tran-
scriptomic changes in motoneurons after a neuroprotective/ -
regenerative treatment. We chose to perform our study with
SOD1G93A mice at 15 week of age with an administration of
G-CSF for 4 weeks. At this age, motor symptom are clearly
established in untreated animals (Pitzer et al., 2008; Henriques
et al., 2011) and G-CSF has a significant beneficial effect on
motor functions and preserves motoneuron counts (Pitzer et al.,
2008). In our study, the altered transcriptome of SOD1G93A alpha
motoneurons has been modified by G-CSF and the expressions
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of 187 genes were partially restored. Genes involved in the main-
tenance of the motor-units, such as Prss12 and CNOT10, were
modulated upon treatment, but effect of G-CSF was also observed
on other different molecular functions such as neuroinflamma-
tion, RNA processing, and energetic metabolism. Completely
unsupervised analyses identified more than half of treated mice as
asymptomatic based on their transcriptomic profile, confirming
the positive effect of the treatment on disease progression.
Modification of the transcriptom was most likely due to a
direct effect of G-CSF on the motor neurons. Motoneurons
express the receptor of G-CSF in basal condition and can upreg-
ulate it after an acute stress in neonatal age (Pitzer et al., 2008;
Henriques et al., 2010a). We have also demonstrated that G-CSF
can rescue motoneurons in a pure apoptotic condition, induced
by sciatic nerve axotomy (Henriques et al., 2010a) and promotes
reinnervation after sciatic nerve crush (Henriques et al., 2011).
However, we cannot formally conclude whether all or most of the
observed changes are due to direct actions of G-CSF onmotoneu-
rons or reflect improved health status of the alpha motoneurons
by indirect treatment effects. Indeed, G-CSF was first described
as a hematopoietic growth factor involved in the proliferation
and differentiation of neutrophils. Despite an abundant litera-
ture on the involvement of neuroinflammation in ALS (Philips
and Robberecht, 2011), there is no evidence that neutrophils have
a role in the initiation or progression of ALS, neither in animal
model nor in ALS patients. Additionally, a recent report suggests
that G-CSF might be involved in response to muscle damage,
which is also a characteristic of ALS(Kruger et al., 2014).
CONCLUSION
G-CSF was able to re-adjust the expression of genes important
for motoneuron survival and function but also genes from other
physiological pathways. The global changes occurring after treat-
ment strengthens the notion of multimodal activity of G-CSF
for preservation of motor units in ALS. Our results complement
the existing data on characterization of G-CSF’s action in mouse
ALS models (Pitzer et al., 2008; Henriques et al., 2010a, 2011;
Naumenko et al., 2011; Pollari et al., 2011) on the gene expres-
sion level. This increases confidence in G-CSF as a promising drug
candidate for ALS.
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